Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prezista (darunavir) dose-response in treatment-experienced HIV-1 patients (POWER 1)
NCT00650832Phase 2Completed
- Sponsor
- Tibotec
- Start
- Oct 2003
- Primary completion
- Feb 2005
01
Overview
A Phase 2 trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Tibotec. Started Oct 2003; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00650832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00650832.